SAN DIEGO – Five studies exploring noteworthy issues in palliative care will be presented at the 2017 Palliative and Supportive Care in Oncology Symposium, taking place October 27-28 at the Manchester Grand Hyatt in San Diego, California. These key abstracts explore several approaches for improving quality of life and quality of care for people with cancer, as well as survivors of cancer.
ALEXANDRIA, Va. – A new study suggests that people with advanced cancer prefer doctors communicate with them face-to-face with just a notepad in hand rather than repeatedly using a computer. These findings will be presented at the upcoming 2017 Palliative and Supportive Care in Oncology Symposium in San Diego, California.
ALEXANDRIA, Va. - Effective clinician communication is a core element of all patient-centered oncology care. The complexities of cancer, and its ever-present association with mortality, require specialized communication skills.
ALEXANDRIA, Va. – The American Society of Clinical Oncology, Inc. (ASCO®) has announced that the first three practices in Spain have received Quality Oncology Practice Initiative (QOPI®) certification through QOPI Certification Program™, LLC (QCP). The accreditations were given today at the European Society of Medical Oncology (ESMO) 2017 Congress in Madrid, Spain.
ALEXANDRIA, Va. - New recommendations on the use of the MammaPrint genomic test issued today will help guide decisions on adjuvant systemic therapy for women with early breast cancer. The recommendations update the American Society of Clinical Oncology (ASCO) 2016 clinical practice guideline on the use of biomarkers in these patients.
The American Society of Clinical Oncology (ASCO) congratulates Dr. Norman "Ned" Sharpless on his appointment as director of the National Cancer Institute (NCI). ASCO is encouraged that NCI will have at its helm an accomplished researcher with experience leading a wide range of clinical and translational research endeavors focused on bringing new insights into cancer prevention and treatment.
CHICAGO – In an early clinical trial, 33 out of 35 (94%) patients had clinical remission of multiple myeloma upon receiving a new type of immunotherapy ̶ chimeric antigen receptor (CAR) T cells targeting B-cell maturation protein or BCMA. Most patients had only mild side effects.
ASCO strongly opposes the Administration’s proposed cuts to federal agencies that support biomedical research and Medicaid for Fiscal Year 2018, including a 21 percent proposed funding cut for the National Institutes of Health (NIH), a 20 percent proposed funding cut for the National Cancer Institute (NCI), and reducing Medicaid funding by more than $600 billion. Such extreme reductions to programs that are critical to research will fundamentally damage our nation’s progress in treating patients and will irreversibly harm our nation’s already fragile biomedical research infrastructure.
ASCO applauds members of the House and Senate for their vote this week to provide a $2 billion increase in funding to the National Institutes of Health (NIH). This marks the first time in more than a dozen years that Congress has provided the NIH with a back-to-back funding increase.
ALEXANDRIA, Va. -- CancerLinQ LLC, a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO®), has announced that Santa Clara Valley Medical Center (SCVMC) in San Jose, Calif. has signed an agreement to participate in the CancerLinQ® platform.
ASCO applauds the California legislature for being the first state body of lawmakers in the nation to consider legislation that is designed to specifically improve clinical pathways in oncology. Clinical pathways, when appropriately designed and implemented, are evidence-based treatment management tools used to support delivery of high-quality cancer care for specific patient presentations.
ALEXANDRIA, Va. – Studies spanning the spectrum of cancer prevention and care, from immunotherapy and precision medicine to survivorship, will be highlighted in the official Press Program for the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO). Research results will be released in advance of and throughout the Annual Meeting, taking place June 2-6 in Chicago.
The American Society of Clinical Oncology (ASCO) has released a set of recommendations to enhance the role of observational cancer research in clinical decision-making. Published in the Journal of Clinical Oncology (JCO), the ASCO research statement discusses the expanding opportunities to utilize observational studies to advance cancer research and supplement the knowledge gained through cancer clinical trials.